Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Oct 10:386:114038.
doi: 10.1016/j.jconrel.2025.114038. Epub 2025 Jul 18.

Advanced peptide nanoparticles enable robust and efficient delivery of gene editors across cell types

Affiliations
Free article

Advanced peptide nanoparticles enable robust and efficient delivery of gene editors across cell types

Oskar Gustafsson et al. J Control Release. .
Free article

Abstract

Efficient delivery of the CRISPR/Cas9 system and its larger derivatives, base editors, and prime editors remain a major challenge, particularly in tissue-specific stem cells and induced pluripotent stem cells (iPSCs). This study optimized a novel family of cell-penetrating peptides, hPep, to deliver gene-editing ribonucleoproteins. The hPep-based nanoparticles enable highly efficient and biocompatible delivery of Cre recombinase, Cas9, base-, and prime editors. Using base editors, robust and nearly complete genome editing was achieved in the human cells: HEK293T (96%), iPSCs (74%), and muscle stem cells (80%). This strategy opens promising avenues for ex vivo and, potentially, in vivo applications. Incorporating silica particles enhanced the system's versatility, facilitating cargo-agnostic delivery. Notably, the nanoparticles can be synthesized quickly on a benchtop and stored as lyophilized powder without compromising functionality. This represents an important advancement in the feasibility and scalability of gene-editing delivery technologies.

Keywords: Base and primer editor; Cell-penetrating peptide (CPP); Diverse cells, including MuSC and iPSC; Gene editing; Protein delivery; Synthetic gene editor delivery.

PubMed Disclaimer

Conflict of interest statement

Declaration of competing interest Si.S. is an inventor on a technology for primary human muscle stem cell isolation and manufacturing (IP: (DE10 2014 216872), 2015 PCT (WO 2016/030371), granted in EU and US). Si.S. and H.E. are co-inventors on a pending patent application on gene editing of human muscle stem cells (European Patent 666 Office 21 160 696.7). Si.S. is co-founder of MyoPax GmbH and MyoPax Denmark ApS.

MeSH terms

LinkOut - more resources